Modeling & Simulation
Strengthen drug development decisions with predictive insights from Modeling techniques such as allometric scaling, PK/PD, exposure-response, and clinical trial simulations.
Modeling & Simulation in Drug Development
Modeling and Simulation (M&S) integrates pharmacokinetics (PK) and pharmacodynamics (PD) data to guide development strategy and accelerate clinical decision-making. By using computational models, researchers can simulate complex biological interactions, predict clinical outcomes, and optimize trial designs—often reducing the need for additional studies.
At Xyzagen, we apply M&S across all stages of development to support key regulatory milestones, refine dose selection, and tailor strategies for specific patient populations. Our modeling approach helps reduce risk, improve trial efficiency, and enable smarter go/no-go decisions.
Key Applications of Modeling & Simulation
Our Modeling & Simulation capabilities help you predict, refine, and validate drug behavior using well-validated quantitative techniques. Key applications include:
How to Use Advanced PK Analysis in Phase 2-3 Trials
Late-stage trials require more sophisticated PK methodologies, often integrating modeling and simulation (M&S). Key applications include:
Mechanistic PK/PD Modeling
Simulate drug absorption, distribution, and interaction with biological targets to inform efficacy and safety projections.
Allometric Scaling
Predict human pharmacokinetics by scaling from preclinical species, helping guide first-in-human dose selection.
Bridging Studies & Extrapolation
Support dose adjustments for pediatrics,geriatrics, and special populations using extrapolated PK/PD models.
Let’s Talk Your Program’s Modeling & Simulation Strategy
Whether you’re planning your first-in-human study or optimizing a Phase 3 trial, Xyzagen’s modeling and simulation services can provide the clarity and confidence you need. Contact us to explore how modeling and simulation can accelerate your development path.
